 |
|
Effects of Subantimicrobial-Dose Doxycycline in the Treatment of Moderate Acne
Robert Skidmore, MD;
Rodney Kovach, MD;
Clay Walker, PhD;
John Thomas, PhD;
Mark Bradshaw, PhD;
James Leyden, MD;
Christopher Powala, BS;
Robert Ashley, MA
Arch Dermatol. 2003;139:459-464.
Objective To determine if treatment with subantimicrobial-dose (SD) doxycycline hyclate (20-mg tablets taken twice daily) improved clinical outcome, had any detectable effect on skin flora, led to overgrowth or colonization of skin by opportunistic pathogens, or resulted in an increase in antibiotic resistance by the surface skin microflora in patients with moderate acne compared with placebo.
Design Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial.
Setting Two university-based clinics.
Subjects Adults (N = 51) with moderate facial acne.
Interventions Patients were randomized to receive SD doxycycline (Periostat; CollaGenex Pharmaceuticals Inc, Newtown, Pa) or placebo twice daily for 6 months.
Main Efficacy Outcomes Primary: changes from baseline in numbers of inflammatory, noninflammatory, and total lesions. Secondary: changes from baseline of individual counts of papules, pustules, and nodules and global assessments of clinical improvement by patient and physician.
Results Forty patients completed 6 months of treatment. At 6 months, the SD doxycycline group had a significantly greater percent reduction in the number of comedones (P<.01), inflammatory and noninflammatory lesions combined (P<.01), and total inflammatory lesions (P<.05) than did the placebo group. They also had significantly greater improvement according to the clinician's global assessment (P = .03). There were no significant differences in microbial counts between groups and no evidence of change in antibiotic susceptibility or colonization by potential pathogens. The treatment was well tolerated.
Conclusions Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.
From the Department of Medicine, Division of Dermatology (Dr Skidmore) and the College of Dentistry (Dr Walker), University of Florida, Gainesville; School of Medicine, Dermatology Section (Dr Kovach) and Department of Pathology, Health Sciences Center (Dr Thomas), West Virginia University, Morgantown; Covance Inc, Princeton, NJ (Dr Bradshaw); School of Medicine, Department of Dermatology, University of Pennsylvania, Philadelphia (Dr Leyden); and CollaGenex Pharmaceuticals Inc, Newtown, Pa (Messrs Powala and Ashley). The financial disclosure statement for these authors appears at the end of this article.
RELATED ARTICLE
Effect of Antibiotics on the Oropharyngeal Flora in Patients With Acne
Ross M. Levy, Eric Y. Huang, Daniel Roling, James J. Leyden, and David J. Margolis
Arch Dermatol. 2003;139(4):467-471.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Acne Through the Ages: Case-Based Observations Through Childhood and Adolescence
Tom and Fallon Friedlander
CLIN PEDIATR 2008;47:639-651.
ABSTRACT
Acne, Antibiotics, and Upper Respiratory Tract Infections
Chan and Shaw
Arch Dermatol 2005;141:1157-1158.
FULL TEXT
Acne
James
NEJM 2005;352:1463-1472.
FULL TEXT
Use of Macrolides and Tetracyclines for Chronic Inflammatory Diseases
Voils et al.
The Annals of Pharmacotherapy 2005;39:86-94.
ABSTRACT
| FULL TEXT
Treatment of Acne Vulgaris
Haider and Shaw
JAMA 2004;292:726-735.
ABSTRACT
| FULL TEXT
THE WHOLE PATIENT
Braswell
Journal of the American Dental Association 2003;134:1165-1166.
FULL TEXT
Low-Dose Doxycycline for Moderate Acne
JWatch Pediatrics 2003;2003:14-14.
FULL TEXT
Low-Dose Doxycycline for Moderate Acne
Journal Watch Dermatology 2003;2003:1-1.
FULL TEXT
Low-Dose Doxycycline for Moderate Acne
JWatch General 2003;2003:3-3.
FULL TEXT
|
